This article is more than 5 years old. Information may no longer be current.
Highlights from FH Global Summit: Cholesterol medication underuse, screening and more
Click Here to Manage Email Alerts
Healio and Cardiology Today present meeting highlights from the FH Foundation’s FH Global Summit on familial hypercholesterolemia, featuring the latest news in the use of cholesterol medication, patient screening, artificial intelligence and more.
Underuse of cholesterol-lowering medications creates ‘missed opportunities’
Despite the improvements that have been made in cholesterol reduction, more efforts are needed to improve usage rates of cholesterol-lowering medications in patients, including those with familial hypercholesterolemia, according to a presentation at the FH Foundation’s FH Global Summit. Read more
Future of FH involves more screening, patient empowerment
Although progress has been made in diagnosing and treating patients with familial hypercholesterolemia, more work is needed in these areas, according to a presentation at the FH Foundation’s FH Global Summit. Read more
AI system successfully identifies patients with FH
A machine learning model was able to analyze large health care encounter databases to identify patients with familial hypercholesterolemia, according to data presented at the FH Foundation’s FH Global Summit. Read more
Disparities of care in patients with FH pose ‘great opportunity’ for awareness
Similar disparities with regards to CVD are also seen in patients with familial hypercholesterolemia, and more work needs to be done to bring awareness and more research into this area, according to a presentation at the FH Foundation’s FH Global Summit. Read more
VIDEO: FH can be vehicle for precision public health
In this video exclusive, Daniel J. Rader, MD, chair of the department of genetics, chief of the division of translational medicine and human genetics, the Seymour-Gray Professor of Molecular Medicine at the University of Pennsylvania Perelman School of Medicine and chief science adviser for the FH Foundation, spoke with Katherine Wilemon, founder and CEO of the FH Foundation, about major takeaways from the FH Foundation’s FH Global Summit, which focused on familial hypercholesterolemia as a driver for precision public health. Read more